Η διερεύνηση των κινήτρων για την επιλογή του αθλήματος της πάλης

Το άθλημα της Πάλης είναι ένα ολοκληρωμένο παιδαγωγικό μέσο που σκοπό έχει την τελειοποίηση της προσωπικότητας του ανθρώπου. Η Πάλη είναι ένα άθλημα επαφής σώμα με σώμα, με αντιπαράθεση δύο αντιπάλων χωρίς χτυπήματα ο ένας στον 2 άλλον, με χρήση τεχνικών λαβών με τα χέρια ή με τα πόδια, για την ελευθέρα Πάλη , με σκοπό την ρίψη του αντιπάλου στο έδαφος και την κατάληψη της επικρατέστερης θέσης. Η Πάλη έχει ένα επιπρόσθετο ιδιαίτερο χαρακτηριστικό, αυτό της ήπιας επιβολής στον αντίπαλο. Στην περίπτωση δηλαδή ενός παλαιστικού αγώνα ο ισχυρότερος επιβάλλεται χωρίς να καταστρέφει τον αντίπαλό του. Ο άνθρωπος λοιπόν μέσω του συμβόλου της Πάλης επιβάλλεται στα στοιχεία της φύσης χωρίς όμως να τα καταστρέφει , δίνοντας με αυτό τον τρόπο το περιθώριο ανάπτυξης και εξέλιξης μίας αρμονικής συμβίωσης. Στην παγκόσμια ιστορία το άθλημα της Πάλης εμφανίζεται ως μέσο άσκησης και αυτοάμυνας , εκεί όμως που για πρώτη φορά εμφανίζεται ως ΑΘΛΗΜΑ (μέσω αγωγής του λαού) είναι ο Σεπτός χώρος της Αρχαίας Ολυμπίας στην Αρχαία Ελλάδα. Το τρέξιμο, ο ακοντισμός, το άλμα, ο δίσκος και η πάλη ήταν τα πέντε αγωνίσματα του πεντάθλου, η πάλη ήταν το τελευταίο αγώνισμα της σειράς, και Θεωρήθηκε τόσο ουσιαστικό που καθόριζε τον τελικό νικητή. Η πάλη είναι ένα άθλημα που απαιτεί εκτεταμένη σωματική και πνευματική προετοιμασία προκειμένου οι αγωνιζόμενοι να ανταποκριθούν στις προκλήσεις της προπόνησης και του αγώνα. Για την ολοκλήρωση της εργασίας διεξάγεται έρευνα ώστε να διαπιστωθεί η συμμετοχή των αθλητών πάλης, τα χαρακτηριστικά τους και το κίνητρό τους για το άθλημα.όχ

Canalicular adenoma with unicystic morphology. A rare entity

Canalicular adenoma (CA) is a benign salivary gland tumor (SGT) almost exclusively affecting the minor salivary glands, predominantly of the upper lip, and exhibiting characteristic histopathologic features. As observed in several other SGTs, a commonly

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Background Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. Methods RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report on the comparison of short-course versus long-course ADT. Key eligibility criteria were indication for radiotherapy after previous radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to add 6 months of ADT (short-course ADT) or 24 months of ADT (long-course ADT) to radiotherapy, using subcutaneous gonadotrophin-releasing hormone analogue (monthly in the short-course ADT group and 3-monthly in the long-course ADT group), daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as metastasis arising from prostate cancer or death from any cause. The comparison had more than 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 75% to 81% (hazard ratio [HR] 0·72). Standard time-to-event analyses were used. Analyses followed intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov , NCT00541047 . Findings Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60–69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 8·9 years (7·0–10·0), 313 metastasis-free survival events were reported overall (174 in the short-course ADT group and 139 in the long-course ADT group; HR 0·773 [95% CI 0·612–0·975]; p=0·029). 10-year metastasis-free survival was 71·9% (95% CI 67·6–75·7) in the short-course ADT group and 78·1% (74·2–81·5) in the long-course ADT group. Toxicity of grade 3 or higher was reported for 105 (14%) of 753 participants in the short-course ADT group and 142 (19%) of 757 participants in the long-course ADT group (p=0·025), with no treatment-related deaths. Interpretation Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy. Funding Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society

Assessing Physicochemical Parameters, Bioactive Profile and Antioxidant Status of Different Fruit Parts of Greek Eggplant Germplasm

Eggplant is an economically important vegetable with a potential for functional food production, mainly due to its high fruit antioxidant capacity. The goal of the present study was to investigate the main physicochemical and antioxidant parameters, and assess the bioactive profiles, of 19 eggplant genotypes of diverse origin, including Greek commercial varieties and hybrids, landraces and the related species S. macrocarpon. For that reason, the physicochemical traits (dry matter, pH, total soluble solids and total acidity) were assessed in the eggplant fruit and some important bioactive compounds (total phenols (TPC), total flavonoids (TFC), total monomeric anthocyanin (TAC), chlorogenic acid (CA) and its isomers neo- and crypto-CA) were assessed both in fruit pulp and peel. In addition, the antioxidant capacity was assessed according to ABTS•+, DPPH• and FRAP assays. The results revealed significant differences between the studied genotypes for all the evaluated traits, for both fruit parts. Solanum macrocarpon showed a distinct bioactive profile and was superior for most of the pulp traits (TFC, neo-CA, crypto-CA, ABTS•+, DPPH• and FRAP). Among the eggplant materials, the landrace ‘KD054/07’ had very high values for pH and some pulp traits (TPC, CA, ABTS•+ and FRAP), while the commercial F1 hybrid ‘Nilo’ was superior for dry matter and most of the peel traits (TPC, TFC, ABTS•+ and FRAP). The Greek commercial variety ‘Langada’ performed well for TAC and peel CA, ABTS•+ and FRAP, while ‘Tsakoniki’ had very high anthocyanin and pulp TPC content. These results constitute a source of information for a subset of the Greek eggplant germplasm and could contribute both to the promotion of Greek varieties of high bioactive and antioxidant value, as well as to the targeted selection of parents in breeding programs

Assessing Physicochemical Parameters, Bioactive Profile and Antioxidant Status of Different Fruit Parts of Greek Eggplant Germplasm

Eggplant is an economically important vegetable with a potential for functional food production, mainly due to its high fruit antioxidant capacity. The goal of the present study was to investigate the main physicochemical and antioxidant parameters, and assess the bioactive profiles, of 19 eggplant genotypes of diverse origin, including Greek commercial varieties and hybrids, landraces and the related species S. macrocarpon. For that reason, the physicochemical traits (dry matter, pH, total soluble solids and total acidity) were assessed in the eggplant fruit and some important bioactive compounds (total phenols (TPC), total flavonoids (TFC), total monomeric anthocyanin (TAC), chlorogenic acid (CA) and its isomers neo- and crypto-CA) were assessed both in fruit pulp and peel. In addition, the antioxidant capacity was assessed according to ABTS•+, DPPH• and FRAP assays. The results revealed significant differences between the studied genotypes for all the evaluated traits, for both fruit parts. Solanum macrocarpon showed a distinct bioactive profile and was superior for most of the pulp traits (TFC, neo-CA, crypto-CA, ABTS•+, DPPH• and FRAP). Among the eggplant materials, the landrace ‘KD054/07’ had very high values for pH and some pulp traits (TPC, CA, ABTS•+ and FRAP), while the commercial F1 hybrid ‘Nilo’ was superior for dry matter and most of the peel traits (TPC, TFC, ABTS•+ and FRAP). The Greek commercial variety ‘Langada’ performed well for TAC and peel CA, ABTS•+ and FRAP, while ‘Tsakoniki’ had very high anthocyanin and pulp TPC content. These results constitute a source of information for a subset of the Greek eggplant germplasm and could contribute both to the promotion of Greek varieties of high bioactive and antioxidant value, as well as to the targeted selection of parents in breeding programs

Recurrence in Oral Premalignancy: Clinicopathologic and Immunohistochemical Analysis

Oral leukoplakia (OL) has a propensity for recurrence and malignant transformation (MT). Herein, we evaluate sociodemographic, clinical, microscopic and immunohistochemical parameters as predictive factors for OL recurrence, also comparing primary lesions (PLs) with recurrences. Thirty-three patients with OL, completely removed either by excisional biopsy or by laser ablation following incisional biopsy, were studied. Selected molecules associated with the STAT3 oncogenic pathway, including pSTAT3, Bcl-xL, survivin, cyclin D1 and Ki-67, were further analyzed. A total of 135 OL lesions, including 97 PLs and 38 recurrences, were included. Out of 97 PLs, 31 recurred at least once and none of them underwent MT, during a mean follow-up time of 48.3 months. There was no statistically significant difference among the various parameters in recurrent vs. non-recurrent PLs, although recurrence was most frequent in non-homogeneous lesions (p = 0.087) and dysplastic lesions recurred at a higher percentage compared to hyperplastic lesions (34.5% vs. 15.4%). Lower levels of Bcl-xL and survivin were identified as significant risk factors for OL recurrence. Recurrences, although smaller and more frequently homogeneous and non-dysplastic compared to their corresponding PLs, exhibited increased immunohistochemical expression of oncogenic molecules, especially pSTAT3 and Bcl-xL. Our results suggest that parameters associated with recurrence may differ from those that affect the risk of progression to malignancy and support OL management protocols favoring excision and close monitoring of all lesions